StockNews.com Begins Coverage on Agile Therapeutics (NASDAQ:AGRX)

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report report published on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group restated a hold rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Agile Therapeutics Stock Up 3.6 %

Shares of AGRX stock opened at $0.45 on Friday. The business’s fifty day moving average is $0.54 and its 200 day moving average is $1.36. The stock has a market cap of $3.05 million, a price-to-earnings ratio of -0.05 and a beta of 1.42. Agile Therapeutics has a twelve month low of $0.20 and a twelve month high of $6.71.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Thursday, March 28th. The specialty pharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter. The company had revenue of $3.62 million for the quarter.

Institutional Investors Weigh In On Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Armistice Capital LLC raised its holdings in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. 10.92% of the stock is currently owned by institutional investors and hedge funds.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.